Newer pharmacologic agents are revolutionizing the treatment of chronic HCV with the recent Food and Drug Administration (FDA) approval of 2 direct-acting antiviral (DAA) medications
Newer pharmacologic agents are revolutionizing thetreatment of chronic HCV with the recent Food and DrugAdministration (FDA) approval of 2 direct-acting antiviral(DAA) medications